May 18, 2024

Growing Influenza Cases To Boost The Growth Of Tamiflu (Oseltamivir Phosphate) Market

Tamiflu (Oseltamivir Phosphate) is an antiviral drug used for treating and preventing influenzas caused by influenza A and B viruses. It works by inhibiting the neuraminidase enzyme of the influenza viruses and prevents their spread in the body. As influenza viruses constantly mutate and evolve, antiviral drugs like Tamiflu provide an effective treatment option. It is prescribed as an oral pill and helps reduce the duration of flu symptoms in adults and children when taken for 5 days. It provides the much needed relief from the virus as there is no vaccine yet to prevent all strains of influenza.

The Global Tamiflu (Oseltamivir Phosphate) Market is estimated to be valued at US$ 464.4 Mn in 2023 and is expected to exhibit a CAGR of 3.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the key trends in the Tamiflu (Oseltamivir Phosphate) market is the increasing demand owing to rising influenza cases globally. As per WHO, influenza affects up to 1 billion people annually and causes severe illness in 3-5 million cases leading to deaths. Certain groups like children, elderly and those with pre-existing medical conditions are at high risk of influenza complications. Furthermore, influenza epidemics occur every year during winter season in temperate regions of the northern and southern hemisphere. The spread of new influenza strains and virus mutations driving seasonal epidemics and pandemics is fueling the demand for effective antiviral drugs like Tamiflu.

Porter’s Analysis

Threat of new entrants: Low due to required technical expertise, high R&D costs and stringent regulations needed for approval. Additionally, established brands have economies of scale advantage.

Bargaining power of buyers: Moderate as there are few substitutes and treatment of influenza virus is important. However, presence of generic alternatives provides option.

Bargaining power of suppliers: High owing to specialized manufacturing process and limited suppliers. Suppliers can demand high prices from buyers.

Threat of new substitutes: Low as Tamiflu is the most effective prescription oral anti-influenza drug. However, alternatives like inhaled zanamivir are available.

Competitive rivalry: High due to presence of major players and generics. Players compete on pricing, quality, and brand positioning.

Key Takeaways

The Global Tamiflu (Oseltamivir Phosphate) Market Size is expected to witness moderate growth, exhibiting 3.1% CAGR over the forecast period, due to increasing prevalence of influenza and awareness regarding timely treatment. The market size for 2023 is estimated at US$ 464.4 Mn.

North America dominated the market with over 30% share in 2023 owing to developed healthcare infrastructure and high healthcare spending. However, Asia Pacific is anticipated to be the fastest growing region due to rising Economies and healthcare investments in countries like China, India.

Key players operating in the Tamiflu (Oseltamivir Phosphate) market are Roche, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Mylan N.V., Apotex Inc., Sandoz AG, Accord Healthcare Ltd. Roche leads the market with patented Tamiflu formulation and global distribution network. Whereas generics players compete on cost and supply capabilities.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it